IV Blood Thinner Beats Oral Drug in Heart Shock Trial
IV Blood Thinner Beats Oral Drug in Heart Shock Trial
IV Blood Thinner Beats Oral Drug in Heart Shock Trial
Key points
اہم نکات
मुख्य बातें
- An intravenous blood thinner helped heart attack patients in cardiogenic shock recover more heart function than an oral drug, results from a 605-patient trial show.
- In the DAPT-SHOCK-AMI trial, patients given IV cangrelor saw their heart's pumping ability improve by 37.9% after one year on ultrasound scans, compared with 21.7% for those given crushed oral ticagrelor, and had 73% lower odds of a dangerous blockage in the heart's small blood vessels.
- The findings, presented at the American Heart Association's Scientific Sessions 2026 and published in Circulation, come from the largest randomised trial of antiplatelet treatment in cardiogenic shock.
- An intravenous blood thinner helped heart attack patients in cardiogenic shock recover more heart function than an oral drug, results from a 605-patient trial show.
- In the DAPT-SHOCK-AMI trial, patients given IV cangrelor saw their heart's pumping ability improve by 37.9% after one year on ultrasound scans, compared with 21.7% for those given crushed oral ticagrelor, and had 73% lower odds of a dangerous blockage in the heart's small blood vessels.
- The findings, presented at the American Heart Association's Scientific Sessions 2026 and published in Circulation, come from the largest randomised trial of antiplatelet treatment in cardiogenic shock.
- An intravenous blood thinner helped heart attack patients in cardiogenic shock recover more heart function than an oral drug, results from a 605-patient trial show.
- In the DAPT-SHOCK-AMI trial, patients given IV cangrelor saw their heart's pumping ability improve by 37.9% after one year on ultrasound scans, compared with 21.7% for those given crushed oral ticagrelor, and had 73% lower odds of a dangerous blockage in the heart's small blood vessels.
- The findings, presented at the American Heart Association's Scientific Sessions 2026 and published in Circulation, come from the largest randomised trial of antiplatelet treatment in cardiogenic shock.
An intravenous blood thinner helped heart attack patients in cardiogenic shock recover more heart function than an oral drug, results from a 605-patient trial show. In the DAPT-SHOCK-AMI trial, patients given IV cangrelor saw their heart's pumping ability improve by 37.9% after one year on ultrasound scans, compared with 21.7% for those given crushed oral ticagrelor, and had 73% lower odds of a dangerous blockage in the heart's small blood vessels. The findings, presented at the American Heart Association's Scientific Sessions 2026 and published in Circulation, come from the largest randomised trial of antiplatelet treatment in cardiogenic shock. The researchers caution the imaging results are hypothesis-generating and do not prove the drug improves survival.
An intravenous blood thinner helped heart attack patients in cardiogenic shock recover more heart function than an oral drug, results from a 605-patient trial show. In the DAPT-SHOCK-AMI trial, patients given IV cangrelor saw their heart's pumping ability improve by 37.9% after one year on ultrasound scans, compared with 21.7% for those given crushed oral ticagrelor, and had 73% lower odds of a dangerous blockage in the heart's small blood vessels. The findings, presented at the American Heart Association's Scientific Sessions 2026 and published in Circulation, come from the largest randomised trial of antiplatelet treatment in cardiogenic shock. The researchers caution the imaging results are hypothesis-generating and do not prove the drug improves survival.
An intravenous blood thinner helped heart attack patients in cardiogenic shock recover more heart function than an oral drug, results from a 605-patient trial show. In the DAPT-SHOCK-AMI trial, patients given IV cangrelor saw their heart's pumping ability improve by 37.9% after one year on ultrasound scans, compared with 21.7% for those given crushed oral ticagrelor, and had 73% lower odds of a dangerous blockage in the heart's small blood vessels. The findings, presented at the American Heart Association's Scientific Sessions 2026 and published in Circulation, come from the largest randomised trial of antiplatelet treatment in cardiogenic shock. The researchers caution the imaging results are hypothesis-generating and do not prove the drug improves survival.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।